[Corrigendum] Anticancer effect of quinacrine on diffuse large B‑cell lymphoma via inhibition of MSI2‑NUMB signaling pathway
Affiliations: Department of Hematology, Ningbo First Hospital, Ningbo, Zhejiang 315010, P.R. China
- Published online on: December 29, 2020 https://doi.org/10.3892/mmr.2020.11813
- Article Number: 174
Copyright : © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Mol Med Rep 17: [Related article:] 522-530, 2018; DOI: 10.3892/mmr.2017.7892
Subsequently to the publication of this paper, an interested reader drew to the authors' attention that, in Fig. 1A on p. 524, the images selected to represent the Control experiments for the SU-DHL-8 and OCI-Ly01 cell lines bore some striking similarities. After having examined their original data, the authors realized that they uploaded the wrong images during the process of compiling this figure.
QC inhibits the proliferation of diffuse large B-cell lymphoma cells. (A) DLBCL cell lines (SU-DHL-8 and Ly01) were incubated with QC and exhibited green fluorescence. Fluorescence intensity gradually weakened with the increase in drug concentration o. Magnification, ×100. (B) Viability of SU-DHL-8 cells and (C) OCI-Ly01 cells following treatment with QC for 48 h. The effect of QC on the growth of the (D) SU-DHL-8 and (E) OCI-Ly01 cell lines is presented. QC, quinacrine.
The corrected version of Fig. 1, showing the correct data for Fig. 1A, is shown on the next page. Note that the replacement of the erroneous data does not affect either the results or the conclusions reported in this paper, and all the authors agree to this Corrigendum. The authors are grateful to the Editor of Molecular Medicine Reports for granting them this opportunity to publish a Corrigendum, and apologize to the readership for any inconvenience caused.